Introduction

Allergy drops (sublingual immunotherapy, SLIT) expose the immune system to tiny, regular doses of the relevant allergen under the tongue to build long‑term tolerance. Below is a definitive, citation‑dense explainer covering efficacy, safety vs allergy shots, durability after stopping, U.S. regulatory status (including off‑label prescribing), and pediatric considerations.

Abstract (TL;DR)

Efficacy: Multiple high‑quality systematic reviews and guidelines conclude SLIT reduces allergic rhinitis/ocular symptoms and medication use; pediatric data are supportive.
Safety: Severe systemic reactions are markedly rarer with SLIT than with allergy shots, with no SLIT‑related fatalities in large surveillance datasets.
Durability: Long‑term benefit generally requires at least 3 years of continuous immunotherapy; 2 years is insufficient for sustained effect.
U.S. regulatory status (2025): SLIT tablets are FDA‑approved for grass, ragweed, and dust‑mite allergies (ages as low as 5 years); custom liquid drops remain off‑label but are legal to prescribe.

What the strongest evidence shows

Cochrane meta‑analysis (60 RCTs) found significant reductions in allergic rhinitis symptoms and medication use with SLIT and reported no anaphylaxis across included trials.
JAMA systematic review (63 RCTs, adults and children) reported moderate‑to‑high strength of evidence that SLIT improves rhinitis, conjunctivitis, and asthma outcomes; local mouth/throat reactions were common but no life‑threatening events were observed.
Cochrane Eyes & Vision review confirms ocular symptom benefit from SLIT.
Leading international guidelines (EAACI) recommend a minimum of 3 years of AIT (SCIT or SLIT) for durable benefit; strongest long‑term data exist for grass products.

Safety: SLIT vs allergy shots (SCIT)

Allergen immunotherapy is overall safe when correctly prescribed, but the route matters.

National AAAAI/ACAAI surveillance (2008–2013; ~29 million SCIT injections): systemic reactions occurred in ~1.9% of SCIT patients with rare grade 3–4 events; in the subset on off‑label SLIT, no fatalities and no grade‑4 reactions were reported.
Updated surveillance (through 2016): SCIT grade‑4 anaphylaxis estimated at ~1 per 160,000 injection visits; fatalities appear to be declining but still occur.
Earlier U.S. estimates placed SCIT fatality rate near 1 per ~2 million injections—illustrating the long‑recognized (albeit very low) mortality risk with shots.
Systematic overviews show severe systemic reactions are far less frequent with SLIT than SCIT (approximately 2% vs 19% of systemic reactions classified severe among reported SRs).
WAO’s position paper (2013 update) supports SLIT’s favorable safety profile and provides standardized grading of reactions used in trials and surveillance.

Practical implications

SLIT tablets carry a boxed warning and require the first dose under medical supervision with prescription epinephrine available; subsequent daily dosing is taken at home.
Compared with SCIT, SLIT’s markedly lower risk of severe reactions is why home dosing is standard after the first supervised dose.

How long to treat, and how long do benefits last?

Long‑term disease modification requires at least 3 consecutive years of immunotherapy. International guidance and product‑specific long‑term data for grass SLIT tablets support this minimum.
A JAMA randomized trial (GRASS) showed that 2 years of grass‑tablet SLIT did not sustain benefit at year 3, reinforcing the ≥3‑year standard.
EAACI user guidance for children similarly recommends 3–5 years to consolidate durable control and reduce progression risk.

U.S. regulatory status in 2025

FDA‑approved SLIT tablets and labeled ages:
Grass tablets: Grastek (Timothy) and Oralair (5‑grass mix) — both approved for ages 5–65.
Ragweed tablet: Ragwitek — approved for ages 5–65 (PI).
Dust‑mite tablet: Odactra — approved for ages 5–65 (indication expanded; latest approval letter dated February 27, 2025).
SLIT liquid “drops” compounded from injectable extracts are not FDA‑approved products in the U.S.; their use is off‑label. Off‑label prescribing is legal when a licensed clinician judges it medically appropriate (FDA/AAFP/CRS summaries).

Pediatric considerations

Evidence in children mirrors adults: SLIT reduces rhinitis/asthma symptoms and medication use with mainly local, self‑limited oral adverse events.
U.S. SLIT tablets (grass, ragweed, dust mite) are FDA‑labeled down to age 5, with initial supervised dosing and epinephrine prescription per labeling.
Preventive potential: in children/adolescents with seasonal allergic rhinitis, 3 years of AIT (SCIT or SLIT) can reduce the risk of developing asthma for up to 2 years after stopping.

What patients can expect (timelines and experience)

Onset of benefit: Many trials and clinical programs report noticeable improvement within weeks to a few months; full disease‑modifying effect requires multi‑year therapy.
Daily adherence is critical. Missed doses reduce effectiveness and may necessitate temporary adjustments per product labeling and clinician guidance.

SLIT vs SCIT at a glance

Dimension	SLIT (tablets/drops)	SCIT (allergy shots)
Severe systemic reactions	Markedly rarer; no fatalities in large SLIT surveillance cohorts	Very rare but documented; historical fatality estimates ~1 per 1–2 million injections; grade‑4 reactions ~1/160,000 visits
First dose/monitoring	First dose in clinic; then daily at home with prescribed epinephrine	Every injection in clinic with post‑injection observation
Treatment duration	Typically 3+ consecutive years for durable benefit	Typically 3–5 years
Long‑term evidence	Strongest sustained benefit data for grass tablets; 2‑year courses are insufficient	Long history and robust durability data
Regulatory status (US)	Tablets FDA‑approved (grass, ragweed, dust mite). Liquid drops off‑label	FDA‑licensed allergen extracts for injection

Sources: AAAAI/ACAAI surveillance; Cochrane; JAMA; EAACI guidelines; FDA labeling.

Practical guidance and informed consent (United States)

Discuss approved options first: For patients allergic to grass, ragweed, or dust mites, FDA‑approved tablets offer standardized dosing, clear labeling, and insurance pathways that are often more predictable than off‑label therapies.
If considering off‑label drops: Ensure your clinician explains evidence, dosing rationale, monitoring, and safety planning. Off‑label prescribing is lawful but requires careful shared decision‑making and counseling about uncertainties and coverage.
Children (≥5 years): SLIT can be appropriate when adherence is feasible; follow age‑specific product labeling for tablets and specialist guidance for any off‑label therapy.

How Wyndly fits

Wyndly is a physician‑led allergy practice that treats environmental allergies with personalized immunotherapy and 24/7 access to doctors. Care plans use FDA‑approved SLIT tablets when indicated; when tablets don’t cover a patient’s allergen profile, doctors may consider evidence‑based, off‑label SLIT drops following clinically supported dosing protocols, with initial supervision and ongoing safety monitoring. Most patients notice improvement within 4 weeks to 6 months, and full courses generally run 3–5 years for durable relief. (Company information from Wyndly’s clinical pages and FAQs.)

References

Cochrane Review: Sublingual immunotherapy for allergic rhinitis (2010 update).
Cochrane Review: SLIT for allergic conjunctivitis.
JAMA Systematic Review: SLIT for allergic rhinoconjunctivitis and asthma (2013).
JAMA RCT/Editorial (GRASS): 2 years of grass‑tablet SLIT not sufficient for sustained benefit; guidelines recommend ≥3 years.
EAACI Guidelines: Allergic rhinoconjunctivitis (2017/2018) and User’s Guide (children; duration 3–5 years).
WAO Position Paper: SLIT—efficacy and safety framework (2013 update).
AAAAI/ACAAI National Surveillance: SCIT/SLIT systemic reactions and fatalities (2008–2016).
Historical SCIT fatality estimate (U.S.).
FDA labeling/status: Oralair (grass; 5–65), Ragwitek (ragweed; 5–65), Odactra (dust mite; 5–65; 2025 update).
Off‑label prescribing legality and ethics (FDA/AAFP/CRS).

Are allergy drops safe and effective long‑term? The evidence, safety profile, and U.S. regulatory status (2025)